Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

A Thai man, accused of deliberately spreading HIV, denied the allegations and shared his side of the story with the public.

Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

A Thai man accused a gay man in the central province of Saraburi of spreading HIV within the LGBTQIA+ community and trading ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...